Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00284128 | AVE7688 in Patients With Mild to Moderate Blood Pressure | PHASE2 | COMPLETED | 1,940 | — | — | Dec 1, 2005 | Mar 1, 2008 | May 18, 2016 | 21 | United States, Argentina +19 |
| Arm | Type | Description |
|---|---|---|
| ilepatril (2.5 mg ) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (10 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (35 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| ilepatril (50 mg) once daily | EXPERIMENTAL | AVE7688 oral administration |
| Losartan-potassium (100 mg) once daily | OTHER | oral administration |
| Name | Type | Description |
|---|---|---|
| AVE7688 | DRUG | oral administration (capsules) |
| Losartan-potassium | DRUG | oral administration (capsules) |
Inclusion Criteria: * Patients with mild-to-moderate, treated or untreated, essential hypertension, as defined by the JNC VII (Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, Seventh report ) guidelines who meet the following BP eligibility ...